Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Greg Lucier: Life after Life Tech
In a single decade, Greg Lucier, 49, transformed the relatively small firm Invitrogen into the international behemoth Life Technologies. Now that Thermo Fisher Scientific has completed its acquisition of Life Tech, Lucier says he may try “to serve in some appointed or possibly even elected capacity.” (For more on Greg Lucier, click here.) Would you vote for Lucier?